If you are looking to invest in Compugen Ltd’s (NASDAQ:CGEN), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio.

Compugen Ltd (CGEN) showcases promising clinical progress and a strong cash position, despite facing revenue and net loss hurdles in Q1 2026.

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

Compugen Ltd. (NASDAQ:CGEN) shares jumped more than 18% in premarket trading on Monday after the biotechnology company ...

Investors in Compugen Ltd (Symbol: CGEN) saw new options become available today, for the December 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

View Compugen Ltd. CGEN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Compugen Ltd. (NASDAQ:CGEN) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On March 2, 2026, Compugen Ltd. (NASDAQ:CGEN) reported fourth-quarter revenue of $67.3 million compared with ...

Shares of Compugen (CGEN) added ~16% in the premarket on Wednesday after the Israel-based biotech announced an agreement with AstraZeneca (AZN) to monetize a portion of future royalties linked to its ...

Compugen Ltd. Annual stock financials by MarketWatch. View the latest CGEN financial statements, income statements and financial ratios.